Filing Flows

Filing Flows › Companies › Immunome › Cash flow

Immunome cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$63.9M in Q2 2026 · −$219M over twelve months

Operating cash flow−$61.7M
Capital spending−$2.2M
Free cash flow−$63.9M

Analysis

In Q2 2026, Immunome generated −$61.7M of operating cash flow and spent $2.2M on capital projects, leaving free cash flow of −$63.9M. That is $13.6M less than in Q2 2025 (−$50.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$209M; the largest uses were operating cash flow ($209M), other investing ($186M), capital spending ($10.3M); besides operations, cash came from other financing ($477M), shares issued ($1.8M); the cash balance rose by $73.8M.

Operating cash flow was −$61.7M against net income of −$73.1M. The largest differences: stock-based pay +$8.8M, prepaid and other assets −$6.9M, payables +$1.2M.

Free cash flow

Immunome: free cash flow by quarterImmunome: free cash flow by quarter−$35.7MQ3 2024−$43.2MQ4 2024−$56.7MQ1 2025−$50.3MQ2 2025−$41.6MQ3 2025−$52.0MQ4 2025−$61.6MQ1 2026−$63.9MQ2 2026
Operating cash flow less capital spending.
Immunome: operating cash flow against capital spendingImmunome: operating cash flow against capital spendingOperating cash flowCapital spending−$34.2M$1.5MQ3 2024−$42.1M$1.1MQ4 2024−$53.1M$3.7MQ1 2025−$49.4M$905KQ2 2025−$40.5M$1.1MQ3 2025−$48.0M$4.0MQ4 2025−$58.6M$3.0MQ1 2026−$61.7M$2.2MQ2 2026
Latest (Q2 2026): Operating cash flow −$61.7M, Capital spending $2.2M.

Capital allocation, year by year

Immunome: where the cash came from (up) and went (down), by fiscal yearImmunome: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$18.2MFY2021: Shares issued $1.4MFY2021: Capital spending −$79K$1.4MFY2021FY2022: Operating cash flow −$28.7MFY2022: Shares issued $32KFY2022: Capital spending −$248K$32KFY2022FY2023: Operating cash flow −$7.6MFY2023: Shares issued $405KFY2023: Capital spending −$831K$405KFY2023FY2024: Operating cash flow −$111MFY2024: Shares issued $22.0MFY2024: Capital spending −$7.2M$22.0MFY2024FY2025: Operating cash flow −$191MFY2025: Shares issued $46.8MFY2025: Capital spending −$9.7M$46.8MFY2025
Over these 5 years operating cash flow totalled −$356M; the largest uses were operating cash flow ($356M) and capital spending ($18.0M). Cash-flow statements as filed.

Where the cash came from and went

Immunome: sources (+) and uses (−) of cash, Q2 2026Immunome: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$365MOther investing−$302MOperating cash flow−$61.7MCapital spending−$2.2MShares issued$1.1M
Immunome: sources (+) and uses (−) of cash, TTM to Q2 2026Immunome: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$477MOperating cash flow−$209MOther investing−$186MCash drawn (+) / kept (−)−$73.8MCapital spending−$10.3MShares issued$1.8M

From profit to cash

Immunome: net income to operating cash flow, Q2 2026Immunome: net income to operating cash flow, Q2 2026Net income−$73.1MDepreciation & amortization$957KStock-based pay$8.8MGains on disposals−$1KPayables$1.2MPrepaid and other assets−$6.9MOperating cash flow−$61.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$61.7M−$2.2M$1.1M$365M−$63.9M
Q1 2026−$58.6M−$3.0M$229K$70.8M−$61.6M
Q4 2025−$48.0M−$4.0M$74K−$381M−$52.0M
Q3 2025−$40.5M−$1.1M$411K−$129M−$41.6M
Q2 2025−$49.4M−$905K$215K$114M−$50.3M
Q1 2025−$53.1M−$3.7M$213K−$114M−$56.7M
Q4 2024−$42.1M−$1.1M$20.5M$12.2M−$43.2M
Q3 2024−$34.2M−$1.5M$509K$9.8M−$35.7M

Immunome: income statement and cash flow

Immunome, Q2 2025: revenue $4.0M (+70% year over year). The chart follows the revenue to costs, profit and cash.

Immunome: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.